Sign in

    Rahul Jasuja

    Managing Director and Senior Research Analyst at Noble Finance

    Rahul Jasuja is a Managing Director and Senior Research Analyst at Noble Finance, specializing in biotechnology sector research with a particular focus on clinical-stage pharmaceutical and life sciences companies. He has covered firms such as XBiotech, where he probes on clinical trial progress, regulatory milestones, and pipeline expansion, and is known for his in-depth industry questions on earnings calls. With over 18 years of experience, Jasuja began his career in biotechnology corporate business development, later serving as Managing Director at Public Ventures LLC from 2004 to 2009 and at Noble Capital Markets since 2011, where he currently leads equity research. He holds advanced professional credentials related to securities analysis and is recognized for his analytical rigor within the biotech investment community.

    Rahul Jasuja's questions to XBiotech (XBIT) leadership

    Rahul Jasuja's questions to XBiotech (XBIT) leadership • Q3 2016

    Question

    Rahul Jasuja of Noble Finance inquired about the expected timeline for the CHMP decision on Xilonix, the status of the European colorectal cancer data publication, enrollment progress for the global Phase III trial, and future plans for non-small cell lung cancer trials, particularly with anti-PD-1 inhibitors.

    Answer

    Founder, President & CEO John Simard stated that the EMA interactions are following a standard course, with a decision possible by mid-December or as late as mid-February. He confirmed the European Phase III study publication is in progress. Medical Director Mike Stecher added that the global colorectal cancer study is on track for an interim analysis in Q1 2017. Regarding non-small cell lung cancer, Mr. Simard noted that while the NCIC collaboration ended, the company is still exploring combinations with EGFR inhibitors and is evaluating opportunities to combine Xilonix with PD-1 inhibitors due to significant investigator interest.

    Ask Fintool Equity Research AI